Home > Services  > Haematology > Dr Danielle Oh

Dr Danielle Oh

Learn more about Monash Health’s Haematology team.

Dr Danielle Oh

Dr Danielle Oh is the Clinical Lead for Cellular Therapies at Monash Haematology. She has been working at Monash Health since 2010 and has a strong interest in malignant haematology and Cellular Therapies. She completed a 1.5-year Lymphoma and transplant Fellowship at the Tom Baker Cancer Centre in Calgary. She is a past recipient of abstract achievement awards at the American Society of Hematology and Canadian Hematology Society. Her PhD thesis is on “dual inhibition of PI3K/BET bromodomain proteins in haematological malignancies” supported by a National Health & Medical Research Council (NHMRC) postgraduate scholarship in 2018 as well as a Haematology Society of Australia & New Zealand (HSANZ) New Investigator scholarship. She was the recipient of The Albert Baikie Award for the best oral presentation by a new investigator at the HSANZ Annual Scientific Meeting in 2021.

Publications

Oh DH, Li H, Duan Q, Villa D, Peters A, Chua N, Owen CJ, Connors JM, Stewart DA. Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis. Biol Blood Marrow Transplant. 2016 May;22(5):941-8.

Oh DH, Chua N, Street L, Stewart DA. Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant. Leuk Lymphoma. 2015 Mar 27:1-6.

Oh DH, Ghosh S, Chua N, Kostaras X, Tilley D, Chu M, Owen CJ, Stewart DA. Comparative effective analysis of different salvage therapy intensities used for diffuse large B-cell lymphoma in Northern or Southern Alberta: an instrumental variable analysis. Leuk Lymphoma. 2015 Jun;56(6):1756-62.

Shortt J, Oh DH, Opat SS. ADAMTS13 Antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med. 2013 Jan 3;368(1):90-2.

Manna M, Lee-Ying R, Davies G, Stewart C, Oh DH, Peters A, Stewart DA. Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world. Leuk Lymphoma. 2018 Jul 3:1-9.